Evidence map›Paper›PMID 32662045›Full record

ArticleJournal of molecular neuroscience : MN2021

Altered ANRIL Methylation in Epileptic Patients.

Sara Mirzajani, Soudeh Ghafouri-Fard, Jafar Mehvari Habibabadi, Mark C Glassy, Arezou Sayad, Mohammad Taheri

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sara MirzajaniDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Soudeh Ghafouri-FardDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Jafar Mehvari HabibabadiIsfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mark C GlassyTranslational Neuro-Oncology Laboratory, San Diego (UCSD) Moores Cancer Center, University of California, Oakland, CA, USA.
Arezou SayadDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ar.sayad@yahoo.com.
Mohammad TaheriUrogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mohammad_823@yahoo.com.ORCID http://orcid.org/0000-0001-8381-0591
Shahid Beheshti University of Medical Sciences · IRIsfahan University of Medical Sciences · IRUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) have regulatory roles in several aspects of cellular physiology. Recent studies have also revealed their role in neuronal differentiation and the pathophysiology of neurologic disorders such as epilepsy. We have recently reported altered expression of a number of lncRNAs in the peripheral blood of epileptic patients in association with their response to antiepileptic drugs. One the most significantly altered lncRNAs in epileptic patients is the antisense non-coding RNA in the INK4 locus (ANRIL), whose expression has been found to be higher in both refractory and non-refractory groups compared with controls. In the current study, we aimed to identify the methylation status of this lncRNA to suggest a potential mechanism for deregulated ANRIL expression. Thus, we assessed the methylation status of the ANRIL promoter in 40 patients with refractory epilepsy, 40 patients with non-refractory epilepsy and 40 normal controls using the high-resolution melting (HRM) method. The HRM results showed hypomethylation of the ANRIL promoter region in both refractory epilepsy and non-refractory epilepsy patients compared with normal controls. This methylation pattern was consistent with the recently reported upregulation of this lncRNA in patients with epilepsy. Thus, we suggest altered methylation of the ANRIL promoter as a potential cause of its aberrant expression in peripheral blood of epileptic patients.

Indexed as

DNA MethylationAdultBase SequenceCase-Control StudiesCpG IslandsDrug Resistant EpilepsyEpilepsyFemaleGene Expression RegulationHumansMagnetic Resonance ImagingMaleMiddle AgedNeuroimagingNucleic Acid DenaturationPromoter Regions, GeneticCDKN2B antisense RNA, humanRNA, Long NoncodingRNA, MessengerANRILEpilepsylncRNAMethylation

Identifiers

PMID32662045
OpenAlexW3040732954

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.